valorion 320 mg tabletki powlekane
orion corporation - valsartanum - tabletki powlekane - 320 mg
octagam 5% 50 mg/ml roztwór do infuzji
octapharma (ip) sprl - immunoglobulinum humanum normale ad usum intravenosum - roztwór do infuzji - 50 mg/ml
riximyo
sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - Środki przeciwnowotworowe - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. dostępne są tylko ograniczone dane dotyczące skuteczności i bezpieczeństwa dla pacjentów, wcześniej leczonych przeciwciała monoklonalne, w tym rytuksymab lub pacjentów, ogniotrwałe do poprzedniej rytuksymab + chemioterapia. cm. rozdział 5. 1 w celu uzyskania dalszych informacji. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rytuksymab pokazywał, że zmniejsza szybkość postępu uszkodzenia stawów jak mierzy się promieniowanie x i ulepszać fizyczną funkcję, w momencie powołania, w połączeniu z metotreksatem. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).
panzyga 100 mg/ml roztwór do infuzji
octapharma (ip) sprl - immunoglobulinum humanum normale - roztwór do infuzji - 100 mg/ml
akvir o smaku malinowym 250 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 250 mg/5 ml
akvir forte o smaku malinowym 500 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 500 mg/5 ml
akvir o smaku truskawkowym 250 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 250 mg/5 ml
akvir forte o smaku truskawkowym 500 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 500 mg/5 ml
abirateron zentiva 500 mg tabletki powlekane
zentiva, k.s. - abirateroni acetas - tabletki powlekane - 500 mg
candesartan + hydrochlorothiazide vitama 16 mg + 12,5 mg tabletki
vitama s.a. - candesartanum cilexetili + hydrochlorothiazidum - tabletki - 16 mg + 12,5 mg